– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...

RNA interference (RNAi) offers a fast and easy system to study gene functions. However, the traditionally used small interfering RNAs (siRNAs) can exhibit pronounced and problematic off-target effects ...

A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

RNA interference (RNAi) is an ancient genetic regulatory mechanism that modern-day scientists are trying to harness. Since its discovery more than 10 years ago, RNAi R&D has run the gamut from ...

Explore RNA interference methods, comparing siRNA and shRNA for gene knockdown, their mechanisms, advantages, and implications for molecular biology research.

Alnylam and Collaborators Publish New Pre-clinical Results on Ex Vivo Applications of RNAi to Enhance Dendritic Cell Vaccines for Cancer – RNAi Silencing of PD-1 Ligands Significantly Boosts Dendritic ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), (the “Company” or “Dicerna”), a leading developer of investigational ...

Ribonucleic acid (RNA) interference is a relatively new technique in which small molecules called short interfering RNA (siRNA) can be inserted into cells to turn off a chosen gene. The potential uses ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

DUBLIN--(BUSINESS WIRE)--The "RNA-interference (RNAi) Market - Growth, Trends, and Forecast (2020 - 2025)" report has been added to ResearchAndMarkets.com's offering. The RNA-interference (RNAi) ...